Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
595 GBX | 0.00% | +2.59% | +0.10% |
May. 07 | Barclays Reduces Fresnillo PT, Maintains Equalweight Rating | MT |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Financials (USD)
Sales 2024 * | 2.98B | Sales 2025 * | 3.05B | Capitalization | 5.56B |
---|---|---|---|---|---|
Net income 2024 * | 245M | Net income 2025 * | 326M | EV / Sales 2024 * | 1.9 x |
Net Debt 2024 * | 98.49M | Net cash position 2025 * | 187M | EV / Sales 2025 * | 1.76 x |
P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
17
x | Employees | 7,260 |
Yield 2024 * |
2.01% | Yield 2025 * |
3.04% | Free-Float | 25% |
Latest transcript on Fresnillo plc
1 week | +2.59% | ||
Current month | +6.63% | ||
1 month | +1.80% | ||
3 months | +22.05% | ||
6 months | +10.80% | ||
Current year | +0.10% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 12-08-14 | |
Director of Finance/CFO | 76 | 08-04-14 | |
Chief Operating Officer | - | 20-11-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 12-04-15 | |
Director/Board Member | 57 | 14-05-15 | |
Director/Board Member | 80 | 08-04-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.14% | 36 M€ | -4.07% | - | |
0.04% | 75 M€ | +8.57% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 595 | 0.00% | 875,639 |
24-05-15 | 595 | +3.39% | 1,024,800 |
24-05-14 | 575.5 | -0.43% | 594,738 |
24-05-13 | 578 | +0.09% | 4,150,759 |
24-05-10 | 577.5 | -0.43% | 853,255 |
Delayed Quote London S.E., May 16, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.10% | 5.55B | |
-10.93% | 149B | |
-3.30% | 120B | |
+4.43% | 75.12B | |
+10.42% | 48.48B | |
+2.78% | 48.46B | |
+33.41% | 40.34B | |
+83.41% | 28.38B | |
+26.10% | 27.07B | |
+54.47% | 18.6B |
- Stock Market
- Equities
- FRES Stock